

ASX Announcement

Medibio Limited – 22 February 2019



Medibio Announces Changes to the Board of Directors and Appointment of Chairman

Melbourne, Australia and Minneapolis, MN USA – 22 February 2019: The Board of **Medibio Limited (MEB or the Company)**(ASX: MEB)(OTCQB: MDBIF), a mental health technology company announces changes to its Board of Directors.

Mr. Andrew Maxwell has resigned from his position as Non-Executive Director of Medibio with immediate effect due to his family commitments and work load related to other endeavours.

Interim Chairman Peter Carlisle, along with the entire Board thank Mr. Maxwell for his valuable service as a Director.

The Medibio Board has resolved to appoint Ms. Melanie Leydin to an Australian Director position of Medibio until a more permanent replacement is secured. Ms. Leydin is a principal of the chartered accounting firm, Leydin Freyer and is Medibio's Joint Company Secretary.

Also, with immediate effect the Board has elected David B. Kaysen to the position of Chairman in addition to his current CEO and Managing Director positions. Given Medibio's current size, the level of engagement of the board members and the importance of managing costs and efficiencies, the Board believes that the combining of CEO and Chairman roles allows for increased efficiency, stability, and cost savings, while allowing the company additional time to explore and consider alternative independent Chair candidates.

As a result of the combined role of CEO and Chair, the Board considers it prudent to appoint a Lead Independent Director and have appointed Mr. Peter Carlisle to undertake this role.

- ENDS -

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic), Perth (WA) and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Further Information:

Website: www.medibio.com.au

Medibio Enquiries:

Kristi Hamilton
Senior Marketing Communication Manager
Medibio Limited
kristi.hamilton@medibio.com.au
T: +1 952 232 0934

Investor Enquiries:

Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231